Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Liabilities and Shareholders Equity: 2020-2024

Historic Liabilities and Shareholders Equity for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $44.2 million.

  • SAB Biotherapeutics' Liabilities and Shareholders Equity rose 241.00% to $183.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $295.9 million, marking a year-over-year increase of 9.19%. This contributed to the annual value of $44.2 million for FY2024, which is 47.35% down from last year.
  • As of FY2024, SAB Biotherapeutics' Liabilities and Shareholders Equity stood at $44.2 million, which was down 47.35% from $83.9 million recorded in FY2023.
  • SAB Biotherapeutics' 5-year Liabilities and Shareholders Equity high stood at $83.9 million for FY2023, and its period low was $44.2 million during FY2024.
  • Over the past 3 years, SAB Biotherapeutics' median Liabilities and Shareholders Equity value was $50.9 million (recorded in 2022), while the average stood at $59.7 million.
  • As far as peak fluctuations go, SAB Biotherapeutics' Liabilities and Shareholders Equity soared by 64.90% in 2023, and later plummeted by 47.35% in 2024.
  • Over the past 5 years, SAB Biotherapeutics' Liabilities and Shareholders Equity (Yearly) stood at $56.5 million in 2020, then surged by 43.52% to $81.1 million in 2021, then slumped by 37.26% to $50.9 million in 2022, then soared by 64.90% to $83.9 million in 2023, then tumbled by 47.35% to $44.2 million in 2024.